Cargando…
Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema
Background: Hereditary angioedema (HAE) due to C1 inhibitor (C1INH) deficiency is characterized by recurrent attacks of edema of the skin and mucosal tissues. Symptoms usually present during childhood (mean age at first attack, 10 years). Earlier symptom onset may predict a more severe disease cours...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499895/ https://www.ncbi.nlm.nih.gov/pubmed/32953229 http://dx.doi.org/10.1089/ped.2020.1143 |
_version_ | 1783583757405519872 |
---|---|
author | Levy, Donald Caballero, Teresa Hussain, Iftikhar Reshef, Avner Anderson, John Baker, James Schwartz, Lawrence B. Cicardi, Marco Prusty, Subhransu Feuersenger, Henrike Pragst, Ingo Manning, Michael E. |
author_facet | Levy, Donald Caballero, Teresa Hussain, Iftikhar Reshef, Avner Anderson, John Baker, James Schwartz, Lawrence B. Cicardi, Marco Prusty, Subhransu Feuersenger, Henrike Pragst, Ingo Manning, Michael E. |
author_sort | Levy, Donald |
collection | PubMed |
description | Background: Hereditary angioedema (HAE) due to C1 inhibitor (C1INH) deficiency is characterized by recurrent attacks of edema of the skin and mucosal tissues. Symptoms usually present during childhood (mean age at first attack, 10 years). Earlier symptom onset may predict a more severe disease course. Subcutaneous (SC) C1INH is indicated for routine prophylaxis to prevent HAE attacks in adolescents and adults. We analyzed the long-term efficacy of C1INH (SC) in subjects ≤17 years old treated in an open-label extension (OLE) of the pivotal phase III Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1 Inhibitor Replacement Therapy (COMPACT) trial. Methods: Eligible subjects (age ≥6 years, with ≥4 attacks over 2 consecutive months before entry into the OLE or placebo-controlled COMPACT trial) were treated with C1INH (SC) 40 or 60 IU/kg twice weekly for 52–140 weeks. Subgroup analyses by age (≤17 vs. >17 years) were performed for key efficacy endpoints. Results: Ten subjects were ≤17 years old [mean (range) age, 13.3 (8–16) years, 3 subjects <12 years old; exposure range, 51–133 weeks]. All 10 pediatric subjects experienced ≥50% reduction (mean, 93%) in number of attacks versus the prestudy period, with a 97% reduction in the median number of attacks/month (0.11). All subjects had <1 attack/4-week period and 4 had <1 attack/year (1 subject was attack free). No subject discontinued treatment due to a treatment-related adverse event. Conclusions: Data from pediatric subjects treated with C1INH (SC) for up to 2.55 years and adult subjects revealed similar efficacy. C1INH (SC) is effective and well tolerated as long-term prophylaxis in children, adolescents, and adults with HAE. |
format | Online Article Text |
id | pubmed-7499895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-74998952020-09-18 Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema Levy, Donald Caballero, Teresa Hussain, Iftikhar Reshef, Avner Anderson, John Baker, James Schwartz, Lawrence B. Cicardi, Marco Prusty, Subhransu Feuersenger, Henrike Pragst, Ingo Manning, Michael E. Pediatr Allergy Immunol Pulmonol Original Research Background: Hereditary angioedema (HAE) due to C1 inhibitor (C1INH) deficiency is characterized by recurrent attacks of edema of the skin and mucosal tissues. Symptoms usually present during childhood (mean age at first attack, 10 years). Earlier symptom onset may predict a more severe disease course. Subcutaneous (SC) C1INH is indicated for routine prophylaxis to prevent HAE attacks in adolescents and adults. We analyzed the long-term efficacy of C1INH (SC) in subjects ≤17 years old treated in an open-label extension (OLE) of the pivotal phase III Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1 Inhibitor Replacement Therapy (COMPACT) trial. Methods: Eligible subjects (age ≥6 years, with ≥4 attacks over 2 consecutive months before entry into the OLE or placebo-controlled COMPACT trial) were treated with C1INH (SC) 40 or 60 IU/kg twice weekly for 52–140 weeks. Subgroup analyses by age (≤17 vs. >17 years) were performed for key efficacy endpoints. Results: Ten subjects were ≤17 years old [mean (range) age, 13.3 (8–16) years, 3 subjects <12 years old; exposure range, 51–133 weeks]. All 10 pediatric subjects experienced ≥50% reduction (mean, 93%) in number of attacks versus the prestudy period, with a 97% reduction in the median number of attacks/month (0.11). All subjects had <1 attack/4-week period and 4 had <1 attack/year (1 subject was attack free). No subject discontinued treatment due to a treatment-related adverse event. Conclusions: Data from pediatric subjects treated with C1INH (SC) for up to 2.55 years and adult subjects revealed similar efficacy. C1INH (SC) is effective and well tolerated as long-term prophylaxis in children, adolescents, and adults with HAE. Mary Ann Liebert, Inc., publishers 2020-09-01 2020-09-16 /pmc/articles/PMC7499895/ /pubmed/32953229 http://dx.doi.org/10.1089/ped.2020.1143 Text en © Donald Levy et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Levy, Donald Caballero, Teresa Hussain, Iftikhar Reshef, Avner Anderson, John Baker, James Schwartz, Lawrence B. Cicardi, Marco Prusty, Subhransu Feuersenger, Henrike Pragst, Ingo Manning, Michael E. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema |
title | Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema |
title_full | Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema |
title_fullStr | Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema |
title_full_unstemmed | Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema |
title_short | Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema |
title_sort | long-term efficacy of subcutaneous c1 inhibitor in pediatric patients with hereditary angioedema |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499895/ https://www.ncbi.nlm.nih.gov/pubmed/32953229 http://dx.doi.org/10.1089/ped.2020.1143 |
work_keys_str_mv | AT levydonald longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT caballeroteresa longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT hussainiftikhar longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT reshefavner longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT andersonjohn longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT bakerjames longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT schwartzlawrenceb longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT cicardimarco longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT prustysubhransu longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT feuersengerhenrike longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT pragstingo longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema AT manningmichaele longtermefficacyofsubcutaneousc1inhibitorinpediatricpatientswithhereditaryangioedema |